Michael C Jensen

List of Publications by Year
in descending order

75 papers	16,294 citations	71102 41 h-index	88630 70 g-index
77 all docs	77 docs citations	77 times ranked	12884 citing authors

#	Article	IF	Citations
1	Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014, 124, 188-195.	1.4	2,080
2	CD19 CARâ€“T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138.	8.2	1,657
3	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine, 2016, 375, 2561-2569.	27.0	1,326
4	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood, 2017, 129, 3322-3331.	1.4	861
5	Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. Journal of Clinical Investigation, 2008, 118, 294-305.	8.2	735
6	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 2008, 112, 2261-2271.	1.4	628
7	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood, 2016, 127, 2406-2410.	1.4	622
8	Bioactivity and Safety of IL13RÎ±2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2015, 21, 4062-4072.	7.0	573
9	Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. Molecular Therapy, 2007, 15, 825-833.	8.2	531
10	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood, 2011, 118, 1255-1263.	1.4	496
11	Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans. Biology of Blood and Marrow Transplantation, 2010, 16, 1245-1256.	2.0	466
12	T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunology Research, 2016, 4, 498-508.	3.4	456
13	Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells. Clinical Cancer Research, 2013, 19, 3153-3164.	7.0	441
14	CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Research, 2006, 66, 10995-11004.	0.9	435
15	The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for<i>In Vivo</i>Antitumor Activity. Cancer Immunology Research, 2015, 3, 125-135.	3.4	406
16	Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. Cancer Research, 2004, 64, 9160-9166.	0.9	342
17	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications, 2016, 7, 12320.	12.8	325
18	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-Bâ€“lineage leukemia effect. Blood, 2003, 101, 1637-1644.	1.4	245

#	Article	IF	Citations
19	CD19 CAR T cell product and disease attributes predict leukemia remission durability. Journal of Clinical Investigation, 2019, 129, 2123-2132.	8.2	244
20	Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8531-8536.	7.1	238
21	The B-cell tumorâ€“associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood, 2010, 116, 4532-4541.	1.4	221
22	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane. Journal of Immunology, 2008, 180, 7028-7038.	0.8	211
23	Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains. Human Gene Therapy, 2007, 18, 712-725.	2.7	199
24	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood, 2012, 119, 72-82.	1.4	186
25	Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. PLoS ONE, 2013, 8, e82742.	2.5	167
26	Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 2012, 51, 263-272.	2.2	158
27	Designing chimeric antigen receptors to effectively and safely target tumors. Current Opinion in Immunology, 2015, 33, 9-15.	5.5	158
28	Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood, 2011, 117, 1888-1898.	1.4	151
29	Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fasâ€“FasL-Dependent AICD. Cancer Immunology Research, 2015, 3, 368-379.	3.4	144
30	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature Medicine, 2021, 27, 1544-1552.	30.7	138
31	Design and implementation of adoptive therapy with chimeric antigen receptorâ€modified T cells. Immunological Reviews, 2014, 257, 127-144.	6.0	134
32	Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells. Journal of Immunology, 2007, 179, 3332-3341.	0.8	133
33	Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. Journal of Immunotherapy, 2012, 35, 689-701.	2.4	128
34	Human T Lymphocyte Genetic Modification with Naked DNA. Molecular Therapy, 2000, 1, 49-55.	8.2	102
35	Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility. Clinical Cancer Research, 2017, 23, 466-477.	7.0	81
36	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. Molecular Therapy, 2018, 26, 280-288.	8.2	76

#	Article	IF	Citations
37	Adoptive transfer of virus-specific and tumor-specific T cell immunity. Current Opinion in Immunology, 2009, 21, 224-232.	5.5	59
38	Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy. Nature Biomedical Engineering, 2019, 3, 783-795.	22.5	56
39	EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget, 2019, 10, 7080-7095.	1.8	52
40	Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes. Journal of Immunotherapy, 2014, 37, 93-104.	2.4	50
41	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood, 2015, 126, 184-184.	1.4	49
42	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer, 2019, 19, 895.	2.6	40
43	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3773-3773.	1.4	39
44	Cellâ€Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigenâ€Presenting Cells for T Cell Activation. Advanced Healthcare Materials, 2019, 8, e1801188.	7.6	38
45	Medulloblastomas Expressing IL13RÎ±2 are Targets for IL13-zetakine+ Cytolytic T Cells. Journal of Pediatric Hematology/Oncology, 2007, 29, 669-677.	0.6	37
46	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy, 2018, 26, 1423-1434.	8.2	37
47	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS ONE, 2016, 11, e0146885.	2.5	34
48	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage. Transplantation and Cellular Therapy, 2022, 28, 21-29.	1.2	31
49	Comparison of naÃ¯ve and central memory derived CD8⁺effector cell engraftment fitness and function following adoptive transfer. OncoImmunology, 2016, 5, e1072671.	4.6	25
50	Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy. PLoS ONE, 2013, 8, e65519.	2.5	25
51	ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunology Research, 2016, 4, 639-641.	3.4	23
52	Biomaterials in Chimeric Antigen Receptor T-Cell Process Development. Accounts of Chemical Research, 2020, 53, 1724-1738.	15.6	23
53	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. Frontiers in Immunology, 2020, 11, 531.	4.8	20
54	CD28-Costimulation Provided through a CD19-Specific Chimeric Immunoreceptor Enhances In Vivo Persistence and Anti-Tumor Efficacy of Adoptively Transferred T Cells.. Blood, 2005, 106, 1278-1278.	1.4	18

#	Article	IF	Citations
55	Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion. Biology of Blood and Marrow Transplantation, 2019, 25, 223-232.	2.0	17
56	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. Cancers, 2021, 13, 1050.	3.7	17
57	Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo. Blood, 2019, 134, 223-223.	1.4	15
58	Chimeric Î³c cytokine receptors confer cytokine independent engraftment of human T lymphocytes. Molecular Immunology, 2013, 56, 1-11.	2.2	12
59	Multiplexed gene transfer to a human Tâ€cell line by combining Sleeping Beauty transposon system with methotrexate selection. Biotechnology and Bioengineering, 2015, 112, 1429-1436.	3.3	10
60	Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses. Blood, 2019, 134, 3869-3869.	1.4	10
61	Synthetic immunobiology boosts the IQ of T cells. Science, 2015, 350, 514-515.	12.6	9
62	Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells. Blood, 2018, 132, 2957-2957.	1.4	9
63	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Molecular Cancer Therapeutics, 2022, 21, 999-1009.	4.1	8
64	Optimized serum stability and specificity of an Î±vÎ²6 integrin-binding peptide for tumor targeting. Journal of Biological Chemistry, 2021, 296, 100657.	3.4	7
65	IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS. Neuro-Oncology, 2021, 23, i29-i29.	1.2	7
66	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer Immunology Research, 2022, 10, 856-870.	3.4	7
67	Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer Immunology Research, 2021, 9, 1047-1060.	3.4	6
68	Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy. Blood, 2018, 132, 4012-4012.	1.4	4
69	Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety. Blood, 2018, 132, 4021-4021.	1.4	2
70	Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence. Blood, 2013, 122, SCI-39-SCI-39.	1.4	2
71	Arming Immune Cell Therapeutics with Polymeric Prodrugs. Advanced Healthcare Materials, 2021, , 2101944.	7.6	1
72	Engineering GVL Through T Cell Gene Transfer. Biology of Blood and Marrow Transplantation, 2008, 14, 5.	2.0	0

#	Article	IF	Citations
73	IL15, but Not IL2, Supports Long-Term Survival and Function of Human and Macaque Antigen-Specific CD8+ T Cell Clones.. Blood, 2004, 104, 3237-3237.	1.4	0
74	Development of a Nonhuman Primate Model for Analysis of the Adoptive Transfer of Antigen-Specific T Cell Clones.. Blood, 2005, 106, 770-770.	1.4	0
75	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, i100-i101.	1.2	0